Brand Reference: Lioresal
| Metric | Verified Benchmark | Source |
|---|---|---|
| Baclofen RxNorm Concept ID | 1292 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0440 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $28.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.30 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $6.80 / mo | 17 Zero-PHI Verified Patient Logs |
Parachlorophenyl GABA derivative acting selectively at Gi/o-coupled metabotropic GABA-B receptors to hyperpolarize monosynaptic/polysynaptic spinal reflex arcs and inhibit transient lower esophageal sphincter relaxations (TLESRs) in PPI-refractory non-acid reflux.
Classified under Spinal & LES Presynaptic GABA-B Metabotropic Receptor Agonist (Rx), Baclofen exhibits a $22.70/month gap between standard U.S. retail cash counters ($28.00) and verified direct-to-patient routing ($5.30) anchored to $0.0440 CMS unit cost.
Pharmacokinetic profiling of Baclofen demonstrates an elimination half-life of 3.5 hours with 75%–85% oral systemic bioavailability; clearance proceeds via 85% excreted unchanged by glomerular filtration (<15% hepatic deamination), reaching clinical onset within 1 hour onset.
Titration schedules for Baclofen (5 mg PO TID x 3 days -> 10 mg PO TID (taper gradually—never stop abruptly)) require excluding abrupt discontinuation after chronic use (withdrawal spasticity/seizure risk); unadjusted egfr < 30 ml/min (encephalopathy toxicity); real-world patient logs highlight somnolence (19% of reports), transient hypotonia weakness (16% of reports) alongside a 80.80% Worth-It consensus.
Across 17 verified cash-pay logs, Baclofen achieves a 80.80% Worth-It rating with out-of-pocket spend averaging $6.80/mo versus $28.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 5 mg PO TID x 3 days -> 10 mg PO TID (taper gradually—never stop abruptly) for Baclofen; monthly out-of-pocket dropped to $4.66 compared with $28.00 retail.
Completed 10 weeks on Baclofen (5 mg PO TID x 3 days -> 10 mg PO TID (taper gradually—never stop abruptly)). Zero notable side effects on steady dosing.
Consistent biomarker response on 5 mg PO TID x 3 days -> 10 mg PO TID (taper gradually—never stop abruptly) Baclofen sourced via Cost Plus Drugs ($6.15/mo cash pay without insurance prior authorization).